The study harnessed Mendelian randomisation, a statistical framework that has become one of the most powerful tools in modern genetic epidemiology. Rather than measuring correlations directly, which are easily distorted by confounding factors and reverse causation, Mendelian randomisation uses naturally occurring genetic variants as instrumental variables. Because these variants are randomly allocated at conception, in the same way that a clinical trial randomly assigns participants to treatment groups, they are largely shielded from environmental confounders. If a genetic variant that raises circulating levels of a protein also raises the risk of depression, the logic of the method suggests that the protein itself may causally influence depression risk, rather than the other way around.

The protein in question, CD40, sits at a critical junction of the immune system. It is a receptor found on the surface of immune cells, most notably B lymphocytes and antigen-presenting cells, and it interacts with a partner molecule called CD40 ligand expressed on activated T cells. When that interaction occurs, it triggers cascades of intracellular signalling that drive B-cell maturation, antibody class switching, and the production of inflammatory cytokines. CD40 signalling is essential for a properly functioning adaptive immune response, but when the pathway is overactive, it can fuel chronic inflammation, autoimmunity and tissue damage. Aberrant CD40 signalling has previously been implicated in conditions including multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and atherosclerosis, which is precisely why the pathway has attracted attention as a therapeutic target.

The locus studied by the team sits in a genomically crowded neighbourhood. The CD40 gene, which encodes the receptor protein, lies close to SLC12A5, a gene encoding KCC2, a potassium–chloride cotransporter that is crucial for neuronal function. KCC2 is one of the best-known regulators of neuronal inhibition: it maintains the low intracellular chloride concentration that allows the neurotransmitter GABA to exert its inhibitory effects in the brain. Loss of KCC2 function shifts the neuronal chloride balance, weakens inhibition, and is linked to epilepsy and altered neuronal excitability. The physical proximity of CD40 and SLC12A5 on the genome creates an analytical challenge that the researchers were careful to confront: genetic variants in this region could influence disease risk through either gene, and standard genetic association studies cannot, on their own, distinguish between the two possibilities.

To resolve that ambiguity, the team turned to colocalisation analysis, a computational technique designed to determine whether two genetic associations, for instance an association with circulating CD40 protein levels and an association with depression, are driven by the same causal variant or by different variants that merely happen to lie in the same region. This distinction matters enormously. If the same variant drives both signals, that supports a shared causal mechanism running through a single gene or protein. If two separate variants are responsible, the apparent overlap may be illusory, a phenomenon known as spatial confounding. Colocalisation methods evaluate the probability that a shared variant explains both traits, and the technique has become a standard safeguard against false positives in protein-based drug target studies.

The results of the analysis, as the study’s title indicates, revealed pleiotropic effects of the CD40/SLC12A5 locus extending across three domains at once: the measurable abundance of CD40 protein in the blood, the risk of depression, and the risk of immune disease. Circulating protein levels are increasingly measured at scale in population biobanks through proteomic platforms that quantify thousands of proteins in plasma. These protein quantitative trait loci, or pQTLs, provide the raw material for studies like this one, allowing researchers to ask whether genetically determined differences in protein abundance translate into differences in disease risk. The CD40/SLC12A5 locus is one of the reported signals for circulating CD40, and the new work tested whether that genetic signal carries consequences for psychiatric and immune outcomes.

The connection between immunity and depression is one of the most actively pursued frontiers in psychiatric research. People with chronic inflammatory diseases experience depression at elevated rates, and large epidemiological studies have repeatedly linked high blood levels of inflammatory markers such as C-reactive protein and interleukin-6 with depressive symptoms. Clinical observations add further intrigue: some patients treated with inflammatory cytokines such as interferon-alpha for hepatitis C or cancer develop severe depressive episodes, and a subset of depression patients shows elevated peripheral inflammation. These converging lines of evidence have spawned the field sometimes called immuno-psychiatry, which seeks to identify biologically defined subtypes of depression that may respond to anti-inflammatory treatment. Genetic studies offer a way to test whether the immune–depression link is genuinely causal or merely a by-product of confounding by lifestyle, socioeconomic factors or reverse causation, where illness and distress alter immune function rather than the reverse.

The new findings carry implications in both directions. For immunology, they suggest that variation at this locus influences susceptibility to immune-mediated disease partly through the same mechanisms that affect circulating CD40 abundance, reinforcing CD40 as a credible drug target for conditions in which the pathway is overactive. Therapeutic agents aimed at the CD40 pathway, including monoclonal antibodies designed to block CD40–CD40 ligand interaction, are already in clinical development for autoimmune conditions. For psychiatry, the genetic link to depression raises the possibility that part of depression’s biological architecture runs through immune signalling, and that individuals with certain genetic profiles might represent a subgroup whose depressive illness is inflammation-associated. That, in turn, hints at a future in which depression is stratified genetically and treated with therapies matched to the underlying biology, an approach that remains aspirational but is increasingly grounded in data of this kind.

The study also illustrates the strengths and the necessary cautions of the modern causal inference toolkit. Mendelian randomisation is only as reliable as its instruments, and genetic variants can exert effects through multiple pathways, a problem known as horizontal pleiotropy that can bias results if not properly modelled. Sensitivity analyses, including weighted median and mode estimators and MR-Egger regression, are typically deployed to detect and adjust for such bias. Meanwhile, colocalisation guards against the distinct pitfall of linked but distinct causal variants. By combining both approaches, the authors of the new study were able to make a stronger case than either method alone would permit, while the close linkage of CD40 and SLC12A5 demanded particularly careful dissection. The region is, in effect, a natural experiment in how human geneticists untangle the contributions of neighbouring genes.

What the work does not yet establish is the precise biological pathway by which CD40 signalling or its modulation influences mood and behaviour, and whether the effects observed at the population level in genetic data will translate into meaningful benefit for individual patients. Animal models of CD40 manipulation have largely focused on autoimmune and neuroinflammatory outcomes, and the connection to depressive-like behaviour remains only partially explored. Human intervention studies targeting the CD40 pathway in depression have not been carried out, and any therapeutic ambition remains speculative. Nevertheless, the convergence of genetic evidence linking a single immune locus to depression risk provides exactly the kind of causal support that has been missing from purely correlational studies, and it gives researchers a concrete molecular hypothesis to test in the laboratory and the clinic.

The research, published in Translational Psychiatry in 2026, represents a collaboration involving Laattoe, Hyppönen and Stacey and colleagues, and forms part of a broader movement to mine biobank-scale genetic and proteomic data for clues about disease mechanisms. As datasets grow and proteomic assays expand, studies of this kind are expected to multiply, systematically screening hundreds of circulating proteins for causal links to psychiatric and immune outcomes. For now, the CD40/SLC12A5 locus stands out as a case study in the power of that approach, and a reminder that the boundaries between immunology and psychiatry are far less rigid than the traditional organisation of medicine would suggest. Depression, long understood primarily through the lens of brain neurotransmitters, increasingly appears also to be a condition in which the immune system’s genetic wiring plays a measurable and potentially modifiable role.

This innovative research centers around two inflammatory indices: the Neutrophil-Percentage-to-Albumin Ratio (NPAR) and the Neutrophil-to-Lymphocyte Ratio (NLR). Both markers, derived from routine blood tests, reflect systemic inflammation and have been linked to various medical conditions, including psychiatric disorders. What sets this study apart is its investigation into how these markers relate differently to the positive and negative symptoms of schizophrenia in males and females, a nuance often overlooked in prior research.

The background of this study highlights the biological principle that sex differences significantly influence immune responses. Males and females exhibit divergent immunological profiles, which may impact how systemic inflammation interacts with brain function and psychiatric symptoms. Given this context, the authors hypothesized that NPAR and NLR would demonstrate differential associations with the severity of schizophrenia symptoms based on sex—a hypothesis that their findings strongly support.

Data for the study were meticulously gathered from 217 patients with schizophrenia of Han Chinese ethnicity, comprising 108 males and 109 females admitted between January 2023 and March 2025. This retrospective design enabled the collection of comprehensive clinical and laboratory data, including neutrophil percentages, absolute neutrophil and lymphocyte counts, and albumin levels. These parameters were instrumental in calculating the NPAR and NLR scores for each patient.

Symptom severity was evaluated using two well-established scales: the Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for the Assessment of Negative Symptoms (SANS). Positive symptoms include hallucinations and delusions, whereas negative symptoms reflect deficits such as emotional withdrawal and lack of motivation. These measures provided a robust framework for correlating inflammatory markers with clinical manifestations.

Strikingly, the results revealed a sex-dependent pattern of association. In male patients, the NLR was positively correlated with the intensity of positive symptoms, suggesting that heightened neutrophil activity relative to lymphocytes may exacerbate psychotic features such as delusions and hallucinations. Conversely, in female patients, the NPAR demonstrated a significant positive association with negative symptoms—implying that the balance between neutrophil percentage and albumin levels might influence the severity of emotional and motivational deficits uniquely in women.

Further analysis uncovered significant interaction effects between sex and the inflammatory markers on the severity of both symptom domains. This suggests that the immune-inflammatory axis’s influence on schizophrenia symptomatology is modulated by biological sex, underscoring the necessity of sex-specific considerations in both research and clinical practice.

This pioneering study’s implications are profound for the future of personalized psychiatry. The distinct inflammatory profiles linked to symptom type and sex could pave the way for individualized treatment strategies, potentially leveraging anti-inflammatory interventions tailored differently for males and females. Moreover, routine blood tests assessing NPAR and NLR could become valuable biomarkers in monitoring disease severity and treatment response.

Beyond clinical applications, the research points to the broader importance of understanding neuroimmune interactions in psychiatric disorders. The immune system’s bidirectional communication with the brain involves complex mechanisms that influence neurodevelopment, neurotransmission, and behavioral outputs. Unraveling sex-specific pathways in this communication enhances our comprehension of schizophrenia’s heterogeneity.

The choice of focusing on NPAR and NLR presents practical advantages. These markers are easily accessible, inexpensive, and routinely measured in clinical settings, making them feasible tools for widespread use. Their incorporation into psychiatric assessments could augment traditional clinical observations with objective biological data, ultimately improving diagnostic accuracy and therapeutic monitoring.

Despite its retrospective nature, the study’s well-defined ethnic cohort and rigorous methodology lend credibility to its findings. Future investigations are warranted to validate these results across different ethnic groups and prospective designs, as well as to elucidate the molecular mechanisms underpinning these sex-specific immune interactions.

In summary, this landmark study published in BMC Psychiatry illuminates the nuanced relationships between systemic inflammation markers and schizophrenia symptoms, contingent upon biological sex. It challenges the convention by emphasizing that males and females may experience and biologically respond to schizophrenia differently, urging the psychiatric community to integrate sex as a critical factor in research and treatment paradigms.

As the understanding of psychiatric disorders evolves beyond neurotransmitter dysfunction alone, studies like this spotlight the immune system’s vital role and open avenues for innovative approaches to mental health disorders. The journey toward personalized psychiatry is complex, but integrating immunological insights holds promising potential to transform outcomes for millions affected by schizophrenia worldwide.

Subject of Research:
Sex-specific associations between inflammatory markers, specifically Neutrophil-Percentage-to-Albumin Ratio (NPAR) and Neutrophil-to-Lymphocyte Ratio (NLR), and the severity of positive and negative symptoms in schizophrenia patients.

Article Title:
Sex-specific associations between Neutrophil-Percentage-to-Albumin Ratio(NPAR) and Neutrophil-to-Lymphocyte Ratio (NLR) with positive and negative symptoms in schizophrenia

Article References:
Zhu, Y., Ren, J. & Fu, Z. Sex-specific associations between Neutrophil-Percentage-to-Albumin Ratio(NPAR) and Neutrophil-to-Lymphocyte Ratio (NLR) with positive and negative symptoms in schizophrenia. BMC Psychiatry 25, 873 (2025). https://doi.org/10.1186/s12888-025-07373-3

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07373-3